News

Bioprojet will be taking part as sponsor for the 16th European Narcolepsy master class 17th May 2019 and for EUNN congress May 18 & 19

Know more

HARMONY BIOSCIENCES ANNOUNCES FILE ACCEPTANCE OF ITS NEW DRUG APPLICATION FOR PITOLISANT

Know more

DATA ON ABUSE POTENTIAL OF PITOLISANT PRESENTED AT 2018 ESRS CONGRESS

Know more

HARMONY BIOSCIENCES PRESENTS 5-YEAR DATA ON PITOLISANT AT INTERNATIONAL NARCOLEPSY SYMPOSIUM

Know more

Bioprojet and Endo Jointly Announce Agreement for Paladin Labs Inc. to Commercialize Pitolisant in Canada

Know more

FAST TRACK AND BREAKTHROUGH DESIGNATIONS BY THE FDA AND FIRST U.S. NARCOLEPSY PATIENTS INCLUDED IN AN EXPANDED ACCESS PROGRAM

Know more

AOP Orphan will distribute Wakix® (pitolisant) from Bioprojet Pharma SAS in Austria, Nordic countries and Central Eastern Europe

Know more

Harmony biosciences acquires US rights to pitolisant from bioprojet; raises $270 million in equity financing

Know more

BIOPROJET PHARMA, a pharmaceutical company

After the discovery, in 1992, of a new molecule in gastroenterology, Bioprojet has created a new company: Bioprojet Pharma, allowing to put this molecule on the market. This is the beginning of a big success.

Know more

BIOPROJET BIOTECH, at the heart of the research

Near Rennes, the research centre Bioprojet Biotech brings together some fifty collaborators which ensure the R&D of the group. Spread in four unities, the Biotech teams are in charged to create new molecules and to realize the preclinical evaluation of these candidate’s drugs.

Know more

BIOPROJET, an international group

Since the beginning of the 2000s, Biotech has extended its international presence with the creation of several subsidiaries. Except France, Bioprojet is currently operational in 9 Europeans countries (Benelux, Italy, United Kingdom, Germany, Spain) and also in Tunis.